|Systematic (IUPAC) name|
|Oral, Sublingual, rectal|
Pyrazolam is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s, and subsequently "rediscovered" and sold as a designer drug and research chemical starting in 2012.
Pyrazolam has structural similarities to alprazolam and bromazepam. Unlike other benzodiazepines pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine. It is most selective for the α2 and α3 receptor subtypes.
- US 3954728, "Preparation of triazolo benzodiazepines and novel compounds"
- Moosmann, B.; Hutter, M.; Huppertz, L. M.; Ferlaino, S.; Redlingshöfer, L.; Auwärter, V. (2013). "Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine". Forensic Toxicology 31 (2): 263. doi:10.1007/s11419-013-0187-4.
- Hester Jr, J. B.; Rudzik, A. D.; Kamdar, B. V. (1971). "6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity". J. Med. Chem 14 (11): 1078–1081. PMID 5165540.
- Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples, B. Moosmann, M. Hutter, L. M. Huppertz and V. Auwärter
- Hester, J. B.; von Voigtlander, P. (1979). "6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity". Journal of Medicinal Chemistry 22 (11): 1390. doi:10.1021/jm00197a021.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|